Curida and PCI Biotech have entered into a manufacturing agreement
Oslo, July 1, 2016 – The pharmaceutical Contract Development and Manufacturing Organization Curida has entered into a manufacturing agreement with the Norwegian biotech company PCI Biotech. Curida will manufacture Amphinex, the lead product candidate from PCI Biotech. Amphinex is currently undergoing international clinical trials for bile duct cancer, a rare cancer disease with a high need of better treatment options.
- The Curida organisation has long experience in manufacturing of sterile pharmaceuticals and a proven track record for manufacturing according to the highest quality standards. Curida also operates at a competitive price level. We are therefore very happy to enter into this agreement for our lead product candidate, says Per Walday, CEO of PCI Biotech.
- Entering into partnerships with biotech companies at an early stage is part of our long-term growth strategy. PCI Biotech is one of the companies that we hope to see succeed with their innovations, and with this partnership we will be in position to provide the services they need when entering large markets, says Leif Rune Skymoen, CEO of Curida.
Curida is located in Elverum, Norway and offers contract manufacturing, development and laboratory services, primarily for large and small companies in the pharmaceutical sector. Curida has GMP and ISO 13485 certified facilities and builds on more than 40 years of experience from pharmaceutical manufacturing. Curida also has offices at Oslo Cancer Cluster Incubator, where they are co-located with PCI Biotech and several other biotech and pharmaceutical companies.
- Oslo Cancer Cluster brings together players from different parts of the value chain, to facilitate the development of new and better cancer treatments. We are happy to see this agreement between PCI Biotech and Curida, which we believe will be add value for our industry and, ultimately, for patients, says Ketil Widerberg, CEO of Oslo Cancer Cluster.
About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalisation (PCI) technology. The PCI technology works by inducing triggered endosomal release and may be used to unlock the true potential of a wide array of therapeutic modalities, such as small molecules, vaccines and nucleic acids.
About Curida
Curida is a Contract Development and Manufacturing Organization (CDMO) within the Pharmaceutical industry, based in Norway. Curida has core competency in state-of-the-art manufacturing of Liquid Pharmaceuticals based on sterile unit-dose Blow-Fill-Seal (BFS) technology and Nasal Spray. The development expertise covers the full service for the development of nasal drug products, and experience on operational excellence is spanning more than 40 years. Curida has produced BFS products since 1989 and offers over three decades of know-how in this technology. Customers range from small start-ups and early stage Biotech companies to Big Pharma.
Contact persons:
Curida AS: Leif Rune Skymoen, CEO, mobile 99 64 94 19
PCI Biotech AS: Per Walday, CEO, mobile 917 93 429
www.curida.no, www.pcibiotech.no